MedTrace Logo

Multi-day Doses in Prevention of Nausea and Emesis

NCT00600353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-09

Study results available
· View outcomes & findings →

Summary

To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).

Conditions

  • Myeloma, Plasma-Cell
  • Lymphoma, Malignant

Interventions

DRUG

Palonosetron

Palonosetron 0.25 mg IV over 30 seconds

DRUG

Aprepitant

Aprepitant 125 mg PO and Aprepitant 80 mg PO

DRUG

Dexamethasone

Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Omar Aljitawi, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600353 on ClinicalTrials.gov